RAFT-AF试验:心衰合并房颤患者基于消融的节律控制与心率控制随机对照研究
RAFT-AF试验为多中心开放标签随机对照研究,纳入411例高负荷阵发性或持续性房颤合并NYHA II-III级心衰且NT-proBNP升高的患者,比较基于消融的节律控制与心率控制。主要复合终点(全因死亡和心衰事件)在两组间无统计学差异(HR 0.71,95%CI 0.49-1.03;P=0.066),但消融组在左室射血分数、6分钟步行距离、NT-proBNP及生活质量方面均显著改善。
要点
- 消融节律控制组主要终点发生率为23.4%,心率控制组为32.5%,差异未达统计学意义(P=0.066)。
- 消融组左室射血分数提升10.1±1.2%,显著优于心率控制组的3.8±1.2%(P=0.017)。
- 两组严重不良事件发生率均为50%,安全性相当。
核心结论
- 在高负荷房颤合并心衰患者中,基于消融的节律控制与心率控制相比,全因死亡或心衰事件无统计学差异,但消融组呈现非显著获益趋势。
研究设计与样本
- 入选标准:高负荷阵发性(6个月内>4次发作)或持续性(持续时间<3年)房颤,NYHA II-III级心衰,NT-proBNP升高。
- 主要终点为全因死亡和所有心衰事件的复合终点,最少随访2年;采用Cox比例风险模型进行时间-事件分析。
- 因数据安全监测委员会判定无效而提前终止。
主要发现
- 主要终点在消融组发生50例(23.4%),心率控制组64例(32.5%),HR 0.71(95%CI 0.49-1.03),P=0.066。
- 左室射血分数变化:消融组10.1±1.2% vs 心率控制组3.8±1.2%,P=0.017。
- 6分钟步行距离变化:消融组44.9±9.1 m vs 心率控制组27.5±9.7 m,P=0.025。
- NT-proBNP平均变化:消融组-77.1% vs 心率控制组-39.2%,P<0.0001。
- 明尼苏达心衰生活质量问卷最小二乘均值差-5.4(95%CI -10.5至-0.3),P=0.0036;房颤对生活质量影响评分最小二乘均值差6.2(95%CI 1.7-10.7),P=0.0005。
关键数值与推荐
- 主要复合终点HR 0.71(95%CI 0.49-1.03),P=0.066,未达到统计学显著性。
- 左室射血分数改善组间差异P=0.017,6分钟步行距离P=0.025,NT-proBNP P<0.0001。
- 生活质量评分组间差异均具有统计学意义(P=0.0036和P=0.0005)。
- 严重不良事件发生率两组均为50%。
临床怎么用
- 对于高负荷房颤合并心衰患者,基于消融的节律控制虽未显著降低死亡和心衰事件,但可改善心功能、运动耐量、神经内分泌指标及生活质量。
- 临床决策时可综合考虑消融对症状和生活质量的获益,以及两组安全性相当的特点。
局限性
- 试验因无效判定提前终止,可能影响主要终点的统计效能。
- 开放标签设计,尽管结局由中央裁定委员会盲法评估,仍可能存在偏倚。
- 随访时间最少2年,长期获益未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) and heart failure (HF) frequently coexist and can be challenging to treat. Pharmacologically based rhythm control of AF has not proven to be superior to rate control. Ablation-based rhythm control was compared with rate control to evaluate if clinical outcomes in patients with HF and AF could be improved. METHODS: This was a multicenter, open-label trial with blinded outcome evaluation using a central adjudication committee. Patients with high-burden paroxysmal (>4 episodes in 6 months) or persistent (duration <3 years) AF, New York Heart Association class II to III HF, and elevated NT-proBNP (N-terminal pro brain natriuretic peptide) were randomly assigned to ablation-based rhythm control or rate control. The primary outcome was a composite of all-cause mortality and all HF events, with a minimum follow-up of 2 years. Secondary outcomes included left ventricular ejection fraction, 6-minute walk test, and NT-proBNP. Quality of life was measured using the Minnesota Living With Heart Failure Questionnaire and the AF Effect on Quality of Life. The primary analysis was time-to-event using Cox proportional hazards modeling. The trial was stopped early because of a determination of apparent futility by the Data Safety Monitoring Committee. RESULTS: From December 1, 2011, to January 20, 2018, 411 patients were randomly assigned to ablation-based rhythm control (n=214) or rate control (n=197). The primary outcome occurred in 50 (23.4%) patients in the ablation-based rhythm-control group and 64 (32.5%) patients in the rate-control group (hazard ratio, 0.71 [95% CI, 0.49-1.03]; P=0.066). Left ventricular ejection fraction increased in the ablation-based group (10.1±1.2% versus 3.8±1.2%, P=0.017), 6-minute walk distance improved (44.9±9.1 m versus 27.5±9.7 m, P=0.025), and NT-proBNP demonstrated a decrease (mean change -77.1% versus -39.2%, P<0.0001). Minnesota Living With Heart Failure Questionnaire demonstrated greater improvement in the ablation-based rhythm-control group (least-squares mean difference of -5.4 [95% CI, -10.5 to -0.3]; P=0.0036), as did the AF Effect on Quality of Life score (least-squares mean difference of 6.2 [95% CI, 1.7-10.7]; P=0.0005). Serious adverse events were observed in 50% of patients in both treatment groups. CONCLUSIONS: In patients with high-burden AF and HF, there was no statistical difference in all-cause mortality or HF events with ablation-based rhythm control versus rate control; however, there was a nonsignificant trend for improved outcomes with ablation-based rhythm control over rate control. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01420393.
引用
- Parkash, Wells, Rouleau, et al. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation. 2022. PMID: 35313733. doi:10.1161/CIRCULATIONAHA.121.057095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。